Affinity Asset Advisors LLC Has $52.13 Million Stock Holdings in AnaptysBio, Inc. $ANAB

Affinity Asset Advisors LLC increased its position in AnaptysBio, Inc. (NASDAQ:ANAB) by 111.4% during the first quarter, HoldingsChannel.com reports. The firm owned 940,000 shares of the biotechnology company’s stock after acquiring an additional 495,308 shares during the quarter. AnaptysBio makes up approximately 2.7% of Affinity Asset Advisors LLC’s holdings, making the stock its 9th largest holding. Affinity Asset Advisors LLC’s holdings in AnaptysBio were worth $52,132,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of ANAB. AQR Capital Management LLC lifted its position in AnaptysBio by 153.3% in the 1st quarter. AQR Capital Management LLC now owns 30,011 shares of the biotechnology company’s stock valued at $558,000 after acquiring an additional 18,165 shares in the last quarter. Creative Planning lifted its holdings in shares of AnaptysBio by 26.9% during the second quarter. Creative Planning now owns 16,854 shares of the biotechnology company’s stock valued at $374,000 after purchasing an additional 3,571 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of AnaptysBio by 1,631.6% during the second quarter. JPMorgan Chase & Co. now owns 247,625 shares of the biotechnology company’s stock valued at $5,497,000 after buying an additional 233,325 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of AnaptysBio during the second quarter valued at $528,000. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in shares of AnaptysBio during the 2nd quarter valued at about $3,348,000.

AnaptysBio Stock Down 1.4%

NASDAQ ANAB opened at $54.15 on Friday. The stock’s 50-day moving average price is $58.38 and its 200-day moving average price is $57.47. The company has a market capitalization of $1.60 billion, a P/E ratio of -50.14 and a beta of 0.68. AnaptysBio, Inc. has a 52 week low of $11.40 and a 52 week high of $72.36.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Tuesday, May 12th. The biotechnology company reported ($1.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($1.20). The business had revenue of $25.56 million for the quarter, compared to the consensus estimate of $18.86 million. Research analysts anticipate that AnaptysBio, Inc. will post -1.35 EPS for the current year.

AnaptysBio declared that its board has approved a stock repurchase program on Friday, March 27th that authorizes the company to repurchase $100,000.00 billion in outstanding shares. This repurchase authorization authorizes the biotechnology company to buy up to 5,352,316.2% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s board believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Weiss Ratings downgraded shares of AnaptysBio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 13th. UBS Group raised their price target on AnaptysBio from $60.00 to $76.00 and gave the stock a “buy” rating in a research note on Wednesday, May 13th. Leerink Partners set a $90.00 price objective on AnaptysBio in a research report on Friday, May 15th. Piper Sandler lowered their target price on AnaptysBio from $95.00 to $93.00 and set an “overweight” rating on the stock in a report on Monday, May 4th. Finally, Wall Street Zen cut AnaptysBio from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 16th. Nine investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $82.00.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.